SHBG and polycystic ovary syndrome: The hyperandrogenic PCOS phenotype is present in 65%–90% of all PCOS cases (Chiaffarino et al., 2022; Kanbour & Dobs, 2022) and is characterised by elevated androstenedione (occurs in 88% of cases), total testosterone (65%) and/or dehydroepiandrosterone sulphate (DHEAS; 30%) (Kanbour & Dobs, 2022), alongside reduced sex hormone binding globulin (SHBG) (Deswal et al., 2018).